1. For a patient with Stage C HF, reduced ejection fraction, and no renal impairment, which of the following classes of medication should initially be considered?

2. Which of the following is the most important next consideration in the management of this patient's heart failure? Case Study

3. What is the next consideration for this patient? Case Study

4. In which patients is the combination of hydralazine and isosorbide dinitrate recommended per current heart failure guidelines?

5. Upon initiating beta-blocker therapy in patients with heart failure the following may be expected:

6. Which of the following should be considered in patients with heart failure and preserved ejection fraction (HFpEF)?

« Return to Activity